Trilogy Capital Inc. Viatris Inc Transaction History

Trilogy Capital Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 16, 2023	BUY	$9.59 - $11.35 $81,371 - $96,304	8,485 Added 3.19%	274,481 $2.71 Million
Q2 2023 Jul 24, 2023	BUY	$9.02 - $10.29 $222,667 - $254,018	24,686 Added 10.23%	265,996 $2.65 Million
Q1 2023 Apr 17, 2023	BUY	$9.2 - $12.26 $1.99 Million - $2.65 Million	216,159 Added 859.44%	241,310 $2.32 Million
Q4 2022 Feb 09, 2023	BUY	$8.72 - $11.56 $39,806 - $52,771	4,565 Added 22.18%	25,151 $279,000
Q3 2022 Oct 21, 2022	BUY	$8.48 - $11.13 $29,340 - $38,509	3,460 Added 20.2%	20,586 $175,000
Q2 2022 Jul 20, 2022	BUY	$9.95 - $12.27 $61,172 - $75,435	6,148 Added 56.0%	17,126 $179,000
Q1 2022 Apr 08, 2022	BUY	$9.81 - $15.4 $107,694 - $169,061	10,978 New	10,978 $119,000

1,102

933M

2.71M

2.4M

Ticker VTRS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 1,212,669,952
Market Cap $15.2B
Description
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, i...

Get notified when there are updates to the investment portfolio of Trilogy Capital Inc., based on Form 13F filings with the SEC.

Stay updated on Trilogy Capital Inc. with notifications on news.